What is it about?

Our cells have an interesting enzyme, called p300/CBP. Its function seems simple enough: to append a small chemical modification onto target proteins to regulate their activities. However, studying its activity in the test tube and inside cells has revealed layers of complex, dynamic interactions that govern this enzyme, and moreover we have come to appreciate its significance in a variety of diseases including cancer, heart disease, diabetes, obesity, and HIV. Astonishingly, this research has not yet translated into a cure, and we make some recommendations to help galvanize this effort.

Featured Image

Why is it important?

This chapter is a resource for researchers interested in p300/CBP. It explains, evaluates, and puts into context a wealth of experimental results and technologies, from landmark historical discoveries to exciting new developments. It is the most thorough review of all the known acetyltransferase inhibitor drugs, and also of all the known potential medical applications of those targeting p300/CBP.


With the guidance of Phil Cole, a renowned innovator in the field of p300 enzymology, I present in this article a summary of information gained from over 500 articles. I created this epic review to provide a comprehensive perspective on a rich body of knowledge and demystify its potential medical applications. I didn't shy away from the bigger picture, nor the more obscure technical details. I especially hope figure 7 will be helpful in explaining the enzymatic function of p300/CBP.

Dr Beverley M. (Dancy) Rabbitts
Washington State University

Read the Original

This page is a summary of: Protein Lysine Acetylation by p300/CBP, Chemical Reviews, January 2015, American Chemical Society (ACS),
DOI: 10.1021/cr500452k.
You can read the full text:



The following have contributed to this page